REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2025
13.11.2025 13:23:00 CET | Business Wire | Press Release
Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2025.
The Group's consolidated turnover in the first nine months of the year reached €1,819.8 million, an increase of 9.0% compared to €1,669.6 million recorded on 30 September 2024.
The indicators for the period are positive. Consolidated EBITDA was €335.5 million, equal to 18.4% of the consolidated revenues. As of September 2024 EBITDA was €275.5 million.
EBIT, from January to September, reached €281.0 million, equal to 15.4% of the consolidated revenues. The corresponding 2024 figure was €224.2 million.
Pre-tax profit, from January to September 2025, was €268.1 million, equal to 14.7% of the revenues. As of September 2024 pre-tax profit stood at €216.0 million.
For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €598.5 million compared to €553.8 million of the third quarter 2024.
EBITDA, from July to September 2025, was equal to €111.8, million, with an EBIT of €92.7 million and pre-tax profit of €88.7 million.
As at 30 September 2025 the Group’s net financial position was positive at €423.1 million. The net financial position as at 30 June 2025 was positive for €362.5 million.
“In the first nine months of 2025 – said Mario Rizzante – our group has been able to grow across all market segments where it operates, thanks to a distinctive ability to adapt to the increasingly pervasive evolution of artificial intelligence.”
“Agentic architectures are opening a new frontier for digital enterprises – continues Mario Rizzante – representing the natural evolution of today’s artificial intelligence models. We are no longer talking only about algorithms that analyze data or generate outputs, but about systems with capabilities of interaction, collaboration, and decisions making, integrating dynamically and in a distributed way within business processes.”
“Today, many companies are already experimenting with agentic solutions, but only few have truly managed to scale them. It is a complex transition that requires not only technology, but also a new architectural mindset: bringing data closer to agents, enabling intelligent orchestration, and above all, ensuring the highest levels of security and integrity in autonomous systems. This is the turning point between experimentation and transformation.”
“For this reason – concludes Mario Rizzante – in the coming months we will continue to invest in building truly agentic AI ecosystems: distributed architectures capable of learning from contexts, adapting in real time, and cooperating safely. Our goal is to help clients bring to life organizations where artificial intelligence is not just a support, but a native component of the decision-making and operational process. This marks the beginning of a new era in software engineering, where every system becomes an increasingly active part of the enterprise.”
The manager responsible for preparing the company's financial reports, Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries
REPLY
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com
This press release is a translation, the Italian version will prevail.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251113771001/en/
Contacts
Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Investor Relation Contacts
Reply
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
Paolo Capitelli
p.capitelli@reply.com
Tel. +390117711594
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom